LabCorp Licenses Sequella Technology for TB Assay Development | GenomeWeb

NEW YORK (GenomeWeb News) – Drug firm Sequella today announced the licensing of its B-Smart nucleic acid-based technology to Laboratory Corporation of America Holdings for an undisclosed amount.

Under the terms of the agreement, LabCorp will use the B-Smart system to develop a laboratory-based antibiotic susceptibility assay for Mycobacterium tuberculosis. LabCorp will also commercially use the assay in the US.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: personal genome approach to RNA-seq read alignment, hematopoietic Systems Biology Repository, and more.

A man is using DNA evidence to argue that he is the rightful heir to the baronetcy of Stichill, the Guardian reports.

As part of an effort to get a diverse group of people to donate their DNA for research, some blood donors in the San Diego area will get their genomes sequenced, according to KPBS.

The comment period on the Department of Health and Human Services' proposal to alter the Common Rule has been extended.